TruSight Oncology Comprehensive
Hybrid-capture NGS assay that profiles DNA and RNA from FFPE solid tumors to detect multiple genomic alterations and signatures for pan-cancer biomarker assessment.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
TruSight Oncology Comprehensive is a hybrid-capture, next-generation sequencing assay that analyzes DNA and RNA from FFPE solid tumors. It detects substitutions, insertions, deletions, copy number changes, and gene fusions across a broad set of cancer-related genes, and can report selected genomic signatures such as MSI or TMB to support comprehensive biomarker-driven treatment planning.
Where this test fits
IVD Manufacturer
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Order this test
If your organization is connected to Casandra, you can place an electronic order forTruSight Oncology Comprehensive directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.